Mani Foroohar
Stock Analyst at Leerink Partners
(2.39)
# 2,546
Out of 5,241 analysts
172
Total ratings
49.48%
Success rate
-2.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAMP Camp4 Therapeutics | Maintains: Outperform | $8 → $9 | $4.15 | +116.87% | 2 | Apr 2, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $27 → $29 | $11.94 | +142.88% | 5 | Mar 3, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $102 → $104 | $73.84 | +40.85% | 17 | Mar 3, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $120 → $118 | $95.65 | +23.37% | 12 | Feb 26, 2026 | |
| RGNX REGENXBIO | Maintains: Outperform | $16 → $20 | $5.66 | +253.36% | 11 | Dec 15, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $75 → $86 | $66.00 | +30.30% | 16 | Dec 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Market Perform | $370 → $351 | $294.30 | +19.27% | 12 | Dec 15, 2025 | |
| MRNA Moderna | Maintains: Underperform | $15 → $18 | $45.72 | -60.63% | 19 | Nov 21, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $4.48 | +346.43% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $2.92 | +139.73% | 13 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $45 → $10 | $16.64 | -39.90% | 2 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $2.85 | +110.53% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $27 | $8.41 | +221.24% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $72 | $26.88 | +167.86% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $6.14 | +258.31% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $10.72 | +21.27% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $11.99 | +141.87% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $1.53 | +1,926.14% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.7875 | +788.89% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $73.18 | -45.34% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.46 | +184.55% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $26.33 | +192.44% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.12 | +17.19% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $47.59 | +59.70% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.97 | +1,625.89% | 4 | May 12, 2022 |
Camp4 Therapeutics
Apr 2, 2026
Maintains: Outperform
Price Target: $8 → $9
Current: $4.15
Upside: +116.87%
Intellia Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $27 → $29
Current: $11.94
Upside: +142.88%
Ionis Pharmaceuticals
Mar 3, 2026
Maintains: Outperform
Price Target: $102 → $104
Current: $73.84
Upside: +40.85%
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Outperform
Price Target: $120 → $118
Current: $95.65
Upside: +23.37%
REGENXBIO
Dec 15, 2025
Maintains: Outperform
Price Target: $16 → $20
Current: $5.66
Upside: +253.36%
BridgeBio Pharma
Dec 15, 2025
Maintains: Outperform
Price Target: $75 → $86
Current: $66.00
Upside: +30.30%
Alnylam Pharmaceuticals
Dec 15, 2025
Maintains: Market Perform
Price Target: $370 → $351
Current: $294.30
Upside: +19.27%
Moderna
Nov 21, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $45.72
Upside: -60.63%
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $4.48
Upside: +346.43%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $2.92
Upside: +139.73%
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $16.64
Upside: -39.90%
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $2.85
Upside: +110.53%
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $8.41
Upside: +221.24%
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $26.88
Upside: +167.86%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $6.14
Upside: +258.31%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $10.72
Upside: +21.27%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $11.99
Upside: +141.87%
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $1.53
Upside: +1,926.14%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.7875
Upside: +788.89%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $73.18
Upside: -45.34%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.46
Upside: +184.55%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $26.33
Upside: +192.44%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.12
Upside: +17.19%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $47.59
Upside: +59.70%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.97
Upside: +1,625.89%